Weekly chemotherapy with radiation versus high-dose cisplatin with radiation as organ preservation for patients with HPV-positive and HPV-negative locally advanced squamous cell carcinoma of the oropharynx.

Abstract

BACKGROUND:

Optimal treatment for locally advanced squamous cell carcinoma of the oropharynx (SCCOP) is not well defined. Here we retrospectively compare survival and toxicities from 2 different organ preservation protocols.

METHODS:

The matched dataset consisted of 35 patients from each trial matched for age, stage, smoking, and tumor human papillomavirus (HPV) status. Patients in the University of Michigan Cancer Center (UMCC) trial 9921 were treated with induction chemotherapy (IC) followed by high-dose cisplatin and radiation in responders or surgery in nonresponders. Patients in the UMCC trial 0221 were treated with weekly carboplatin and paclitaxel and radiation.

RESULTS:

Survival was comparable for both studies and did not differ significantly across each trial after stratifying by HPV status. Grade 3 and 4 toxicities were more frequent in UMCC 9921. At 6 months posttreatment, gastrostomy tube (G-tube) dependence was not statistically different.

CONCLUSION:

These data suggest that survival outcomes in patients with locally advanced SCCOP are not compromised with weekly chemotherapy and radiation therapy, and such treatment is generally more tolerable.

• Authors: Irina Y Dobrosotskaya, Emily Bellile, Matthew E Spector, Bhavna Kumar, Felix Feng, Avraham Eisbruch, Gregory T Wolf, Mark E P Prince, Jeffrey S Moyer, Theodoros Teknos, Douglas B Chepeha, Heather M Walline, Jonathan B McHugh, Kitrina G Cordell, P Daniel Ward, Serena Byrd, Jessica H Maxwell, Susan Urba, Carol R Bradford, Thomas E Carey, Francis P Worden
• Journal: Head & neck (Head Neck) Vol. 36 Issue 5 Pg. 617-23 (May 2014) ISSN: 1097-0347 [Electronic] United States
• PMID: 23596055 (Publication Type: Clinical Trial, Phase II, Comparative Study, Journal Article)
• Copyright: Copyright © 2013 Wiley Periodicals, Inc.

Chemical References

• Antineoplastic Agents
• Carboplatin
• Paclitaxel
• Cisplatin

Topics

• Aged
• Antineoplastic Agents (therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Carboplatin (therapeutic use)
• Carcinoma, Squamous Cell (drug therapy, mortality, pathology, radiotherapy, virology)
• Cisplatin (administration & dosage)
• Combined Modality Therapy
• Disease-Free Survival
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• Female
• Follow-Up Studies
• Human papillomavirus 6 (isolation & purification)
• Humans
• Kaplan-Meier Estimate
• Male
• Middle Aged
• Neoplasm Invasiveness (pathology)
• Neoplasm Staging
• Organ Preservation
• Oropharyngeal Neoplasms (drug therapy, mortality, pathology, radiotherapy)
• Paclitaxel (therapeutic use)
• Proportional Hazards Models
• Prospective Studies
• Pulse Therapy, Drug (methods)
• Radiotherapy, High-Energy (methods)
• Risk Assessment
• Serologic Tests
• Survival Rate
• Time Factors
• Treatment Outcome